| Document |
Document Title |
|
WO/2018/198975A1 |
Provided is a light-emitting element having excellent luminance life. Disclosed is a light-emitting element comprising a positive electrode, a negative electrode, a first organic layer provided between the positive electrode and the nega...
|
|
WO/2018/173058A1 |
The present invention provides processes for the preparation of diverse heterocyclic scaffolds from alpha-enaminone building bloc of formula (I).
|
|
WO/2018/174826A1 |
This invention relates to a method for producing an alkenyl 1 -aminocyclopropane-1 -carboxylic acid of Formula I wherein R1 is a protecting group, n is an integer between 1 and 10, and A and B are chiral centres such that when A is S, B ...
|
|
WO/2018/167800A1 |
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...
|
|
WO/2018/159834A1 |
Provided are a donor-acceptor type compound having a novel structure and an application of the donor-acceptor type compound. This enamine compound is represented by general formula (1) (in the formula: R1 represents an electron-accepting...
|
|
WO/2018/154414A1 |
This invention relates to a method for the manufacture of optically pure (S)-6- chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-
2H-3,1 -benzoxazin- 2-one. Specifically, this invention relates to a flow synthesis method for t...
|
|
WO/2018/149370A1 |
Disclosed are a fluorenylaminoketone photoinitiator, a preparation method thereof and a UV photocurable composition containing same. The photoinitiator comprises a compound having a structure as shown in general formula (I) or a derivati...
|
|
WO/2018/138362A1 |
The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl] (phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)
acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, aut...
|
|
WO/2018/133859A1 |
Disclosed herein are compounds and methods for using the same for the detection of hydrogen peroxide in situ. The compounds can include compounds of Formula (I), Formula (II), or Formula (III), or a salt thereof, wherein X1 is a monovale...
|
|
WO/2018/136890A1 |
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...
|
|
WO/2018/129411A1 |
Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases o...
|
|
WO/2018/126072A1 |
The present invention provides polycyclic oxothioxoimidazolidines, dioxoimidazolines, oxothioxooxazolidines, dioxooxazolidines, and related compounds, which are useful as integrin agonists. Methods for the treatment of integrin-mediated ...
|
|
WO/2018/115096A1 |
The present invention relates to a new process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name Delmopinol. The invention also relates to three key intermediates 1-chloro-4- propylhept-3-ene, 1-iodo-4-propylhept...
|
|
WO/2018/115111A1 |
The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propy...
|
|
WO/2018/115116A1 |
The present invention relates to a new process for producing intermediates useful in the manufacture of 2-(3-(4-propylheptyl)morpholino)ethan-l-ol. The invention also relates to intermediates l-chloro-4-propylhept-3-ene and l-iodo-4-prop...
|
|
WO/2018/114887A1 |
The present invention provides an improved process for the manufacture (R)-6- hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethyl-eth
ylamino-ethyl]-2H-1,4- benzoxazin-3(4H)-one, in high purity and high yield, through the use of 1,1...
|
|
WO/2018/111619A1 |
Pharmaceutical compositions for treating or mitigating glaucoma are described, the compositions comprising several separate components for an improved effect. Methods for fabricating the compositions and using them are also described.
|
|
WO/2018/112081A1 |
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2', R3, R4, R5,...
|
|
WO/2018/106825A1 |
Disclosed herein are salts and polylmoprhs of (2S)-2-[(S)-(ethoxyphenoxy)phenylmethyl]morpholine (esreboxetine) as shown in Formula I, wherein an acid is selected from adipic, L-ascorbic, L-aspartic, fumaric, glycolic, hydrochloric, male...
|
|
WO/2018/101329A1 |
The purpose of the present invention is to develop a therapeutic agent for inflammatory diseases such as inflammatory bowel disease and NASH, said therapeutic agent having few adverse effects and high efficacy. The present invention prov...
|
|
WO/2018/102419A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2018/095488A1 |
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...
|
|
WO/2018/069842A1 |
This invention relates to 4-substituted phenylamine derivatives of the general formula (I), wherein R1 to R8 and A have the meanings as defined in description. The invention further relates to methods for their preparation and use of sai...
|
|
WO/2018/069841A1 |
This invention relates to 4-substituted phenylamine derivatives of the general formula (I), wherein R1 to R9 and A have the meanings as defined in description. The invention further relates to methods for their preparation and use of sai...
|
|
WO/2018/065768A1 |
The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having u...
|
|
WO/2018/057430A1 |
Amine substituted morpholino oligonucleotides, other than the classical N,N-dimethylamino PMO analogue, and methods of efficiently synthesizing these oligonucleotides with high yield are provided. Morpholino oligonucleotides having thiop...
|
|
WO/2018/057134A1 |
The present invention relates to an unsaturated fluorinated ether or amine compound of formula (I) with low global warming potential and method of making the compound (I), where RH 1 is and RH 2 are independently selected from H or CH3, ...
|
|
WO/2018/051930A1 |
The purpose of the present invention is to provide: a composition for forming a resist lower-layer film that allows the formation of a resist lower-layer film with outstanding flatness and outstanding solvent resistance and etching resis...
|
|
WO/2018/051278A2 |
The present invention relates to a compound of formula (I) based on enamine derivatives and used as organic hole conductors or hole transporting material in an optoelectronic or photoelectrochemical device. The present invention relates ...
|
|
WO/2018/048261A1 |
The present invention relates to a novel spiroquinone derivative compound, a production method thereof, and a pharmaceutical composition for preventing or treating neurological disorders which contains the compound as an active ingredien...
|
|
WO/2018/044896A1 |
Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the tr...
|
|
WO/2018/039096A1 |
A composition includes a perfluorinated propenylamine represented by the following general formula (1): Each occurrence of Rf1 and Rf2 is: (i) independently a linear or branched perfluoroalkyl group having 1-8 carbon atoms and optionally...
|
|
WO/2018/030550A1 |
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.
|
|
WO/2018/017490A1 |
The present invention relates to novel sulfonamide derivatives, to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants, ...
|
|
WO/2018/011676A1 |
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one, and its intermediates, in high yield and purity.
|
|
WO/2018/007217A1 |
The present invention relates to novel sulfonamide derivatives, to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controlling the growth of plants, ...
|
|
WO/2018/009256A1 |
The present invention relates to ampakines, including low impact ampakines, and pharmaceutical compositions and methods employing ampakines for treating central nervous system (CNS) disorders, including attention deficit disorders. Novel...
|
|
WO/2018/004289A2 |
The present invention relates to a benzoxazine-based mixture and a use thereof and, more specifically, to a benzoxazine-based mixture and a use of a cured product in which the benzoxazine-based mixture is cured, wherein the benzoxazine-b...
|
|
WO/2018/004066A1 |
The present invention relates to an aryl ethane derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, an...
|
|
WO/2018/004065A1 |
The present invention relates to an aryl ethane derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, an...
|
|
WO/2017/216299A1 |
The object of the present invention are compounds comprising at least one donor group and at least one acceptor group, as described herein, which are characterized by a pronounced CT character. The invention also relates to the use there...
|
|
WO/2017/215549A1 |
Disclosed are an organic electroluminescent compound and an application thereof. The structural formula of the compound is as shown in general formula (1). The material has good fluorescence quantum efficiency and electroluminescence eff...
|
|
WO/2017/205425A1 |
Described herein are molecules for use in organic light emitting diodes comprising at least one moiety A, at least one moiety D, and at least one moiety B.
|
|
WO/2017/205880A1 |
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesi...
|
|
WO/2017/196805A1 |
The present disclosure provides a curable system containing a benzoxazine and a benzothiazole sulfenamide. The curable system may be catalyzed at temperatures generally used to cure multifunctional epoxy resins yet exhibits improved pot-...
|
|
WO/2017/184604A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2017/179661A1 |
According to the present invention, a charge transport polymer which contains a structural unit having an N-aryl phenoxazine skeleton is configured and is used as a charge transport material.
|
|
WO/2017/157322A1 |
Provided are a compound represented by formula I, a raceme thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof, a preparation method therefor, a pharmaceutical composition comprising th...
|
|
WO/2017/155102A1 |
Provided is a compound which comprises 2 or more donor groups having different structures and a linking group that links these donor groups, wherein the linking group is an aromatic group constituted from 1 or more benzene rings optional...
|
|
WO/2017/155686A1 |
An acyclic fluorinated compound of formula (I) is amine -containing acyclic hydrofluoroethers. The acyclic fluorinated compound is useful as heat transfer, solvent cleaning, fire extinguishing agents and electrolyte solvents and additives.
|
